The purpose of this FOA is to provide support for planning activities for late phase (phase II and beyond) single-site or multi-site investigator-initiated clinical trials that address critical clinical questions within the mission of the National Heart, Lung, and Blood Institute (NHLBI) and that require non-traditional clinical trial designs with the opportunity for statistical novelty and/or innovation. The FOA will support the development of feasible and well-designed clinical trials utilizing consultative services provided by the Innovative Clinical Trials Resource (ICTR) (N01). The ICTR contract has been recently awarded to Berry Consultants.

The submission deadlines are in July and October 2018.

If you are interesting in applying for this funding opportunity, please contact OSRP. Completed proposals are due in OSRP at least two business days prior to the deadline set by the sponsor.